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nally thought to be poor3; however, more recent reports
demonstrate a good prognosis for localized neoplasms.4-6
There have been claims of correlation between certain
clinical, radiographic, and pathologic findings and sur-
vival.6-8 Some researchers have claimed a predilection
for BAC in women and no correlation to cigarette smok-
ing. Because of these claims with conflicting reports, we
reviewed our experience with BAC to see whether we
could corroborate or refute some of these claims.
B ronchoalveolar carcinoma (BAC) is considered asubtype of adenocarcinoma.1 Since first described
in 1876,2 it has been called by a variety of different
names (alveolar cell carcinoma, bronchiolar carcinoma,
and BAC). The characteristic pathologic features of
BAC are the presence of aerogenous spread and evi-
dence of advancement along the alveolar wall. BAC can
coexist with adenocarcinoma, and overlap within the
same tumor often occurs. Prognosis for BAC was origi-
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Methods
We studied 119 patients with BAC histologically confirmed
at the Massachusetts General Hospital from 1977 to 1995.
BAC was defined, according to World Health Organization
criteria, as a variant of adenocarcinoma in which more than
one half of the malignant cells grew along the alveolar walls
and within alveolar spaces with preservation of the alveolar
framework of the lung. The records of all patients were
reviewed for clinical characteristics: symptoms, smoking sta-
tus, method of diagnosis, operative findings and procedure,
complications, and long-term survival. All living patients or
family were contacted by telephone. A lung resection was
considered curative when all known BAC was removed and
no microscopic tumor was left in the surgical margin.
Operative death was defined as all deaths occurring within 30
days of operation.
All chest radiologic findings were reviewed to determine
the characteristics because computed tomography scans were
not available for all patients during the period of study.
Radiographic lesions were classified according to the pres-
ence of a mass or infiltrate. The lesion was considered an
infiltrate when it was a poorly delineated opacity without
defined borders. The infiltrative lesions were subclassified
according to unilateral or bilateral, and within one or more
lobes. The mass lesions were subclassified as single or multi-
ple, and larger or smaller than 3 cm, if single.
All solitary neoplasms were postoperatively staged accord-
ing to the current International TNM Classification System
for Lung Cancer.9 When multiple lesions were resected, the
patients were separated simply as unilateral or bilateral.
Gross and microscopic pathologic features were studied.
Grossly, the tumors were characterized according to the fol-
lowing features: solitary, diffuse, or multifocal; well-defined
nodule, ill-defined single mass, or pneumonic. Micro-
scopically, 8 features were evaluated: tumor border (sharp, ill
defined, mixed); aerogenous spread (yes or no); subtype of
adenocarcinoma (acinar, papillary, bronchoalveolar, and the
percent calculated accordingly); pattern (mucinous, muci-
nous-sclerosing, nonmucinous, nonmucinous-sclerosing);
cell type (type II pneumocyte, Clara cell, colonic mucinous,
endocervical mucinous, or mixed); nuclear grade (well dif-
ferentiated, moderately differentiated, poorly differentiated);
mitotic activity (number per 10 high-power fields); and the
degree of lymphocytic inflammation (quantitating from 0
through 3).
Clinical features of sex, symptoms, and smoking status
were analyzed for the incidence of disease. The relationship
between clinical, radiologic, and pathologic findings were
examined. Symptoms, smoking status, the presence of a mass
or infiltrate, mucinous or nonmucinous, sclerosing or non-
sclerosing, and the percent of BAC cells were chosen and
examined for the relation to each other. Factors were then
analyzed according to their impact on survival.
Statistics. The survival analysis was estimated by the
Kaplan-Meier actuarial method,10 with the date of initial
Table I. Operative procedures
Procedure N
First operation 114
Lobectomy 73
+Wedge resection 5
+Segmentectomy 2
+Chest wall 1
+Diaphragm 1
Bilobectomy 6
Pneumonectomy 7
+Diaphragm 1
+Sleeve pneumonectomy 1
Segmentectomy 8
+Wedge resection 1
Wedge resection 13
Open lung biopsy 7
Subsequent operations 11
Completion pneumonectomy 3
Lobectomy 4
+Wedge 1
Segmentectomy 2
Wedge resection 1
Table II. Pathologic findings (n = 119)
Findings N
Histologic evidence
Mucinous 26
Nonmucinous 82
Mucinous + nonmucinous 11
Sclerosing 96
Associated scar 72
Cell type
Clara 69
Endocervical mucinous 9
Type II 6
Colonic mucinous 1
Mixed 34
BAC %
50% 20
60% 23
70% 14
80% 22
90% 23
100% 17
Nuclear grade
Well-differentiated 21
Moderate 83
Poor 15
Mitoses (per 10 high-power fields)
0 68
1 41
2 7
Lymphocyte infiltration
Grade 0 6
Grade 1 38
Grade 2 41
Grade 3 22
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operation as the starting date. The difference of variables on
survival was analyzed with the log-rank rest for cosorted
data.11 Qualitative data were analyzed with c 2 tests. Cox mul-
tivariate analysis was used to evaluate all factors. All reported
P values are 2-tailed.
Results
Clinical findings. Of 119 patients available for study,
44 were men and 75 were women. Ages ranged from 15
to 83 years (mean, 65.5 ± 11.7 years) in men and from
29 to 75 years (mean, 63.1 ± 9.7 years) in women.
Eighty-five patients (71%) were asymptomatic. Cough,
dyspnea, and sputum production were the most com-
mon symptoms. Eighty patients (68%) were current or
former smokers, and 39 patients were nonsmokers.
Radiologic findings. Chest radiographs showed a
mass lesion in 94 patients and infiltrating lesion in 25
patients. Among mass lesions, a single lesion was pre-
sent in 80 patients (≤3 cm in 58 patients and >3 cm in
22 patients). Multiple lesions were present in 14
patients (unilateral in 10 patients and bilateral in 4
patients). Among infiltrating lesions, 15 patients had
unilateral lesions and 10 patients had bilateral lesions.
Method of diagnosis. The diagnosis of malignancy
was made by sputum cytologic evaluation in 4 patients,
bronchoscopic examination in 12 patients, needle aspi-
ration biopsy in 40 patients, prior brain surgical proce-
dure in 1 patient, and surgical resection in 62 patients.
Operative procedure. One hundred seven patients
underwent surgical resection; 7 patients had open lung
biopsies, and 5 patients had transbronchial biopsy only.
Five patients underwent multiple surgical procedures
for tumor recurrence. The operative procedure for the
first, second, or subsequent resections are shown in
Table I. The most common procedure was lobectomy
(64%, first surgical procedure).
Morbidity and mortality. There were 3 operative
deaths (mortality, 2.4%). Cause of death was cerebral
vascular accident at day 7, sudden cardiac arrest prob-
ably the result of pulmonary embolism or myocardial
infarction just after discharge at day 22, and pneumo-
nia followed by sepsis and gastrointestinal bleeding at
day 9. Postoperative complications occurred in 34
patients (27.2%). One quarter of the complications
were major. 
Pathologic findings. One hundred two first-time sur-
gical procedures were considered curative. Five
patients did not undergo curative resections because of
tumor at the resection margins on histologic examina-
tion. There were 11 reoperations in 5 patients; 8 were
deemed curative. Of the 5 patients undergoing multiple
operations, 3 patients had similar pathologic findings
as the first operation, and 2 patients had different find-
ings. The pathologic findings are listed in Table II.
Findings of aerogenous spreading were seen in 113 of
119 patients. Most of the tumors in this series did not
show signs of mucin production (82/119 tumors). Most
of the tumors had evidence of sclerosis present or were
associated with the presence of a scar. The most com-
mon cell type seen was the Clara cell. Other cells iden-
tified included endocervical mucinous, type II pneu-
mocyte, or colonic mucinous cells. Approximately
29% of tumors had a mixture of different types of cells
present. A pure bronchoalveolar cell pattern was seen
in only 17 of 119 patients. Most tumors were a mixture
of bronchoalveolar cell carcinoma and adenocarcinoma
with percentages of BAC ranging from 50% to 90%.
Most tumors were graded as moderately differentiated
(83/119 tumors) with comparable numbers of well and
poorly differentiated tumors. Sixty-eight patients had
no mitotic activity seen on 10 high-power microscopic
examinations; 41 patients had only 1 mitosis seen per
10 high-power fields, and 7 patients had 2 or more
mitoses per 10 high-power fields. A qualitative assess-
ment was made of the presence of lymphocyte infiltra-
tion into the tumors. Eighty-five patients had grade 0 to
Table III. Stage of tumor in patients undergoing
resection
Stage N
I
T1 N0 55
T2 N0 26
II
T1 N1 3
T2 N1 4
III
T3 N0 2
T1 N2 2
IV
T1 N0 M1 1
Multiple 14
Table IV. Clinical, radiographic, and pathologic 
correlations
Mass (%) Infiltrate (%) P value
Symptoms 16 76 <.0001
Asymptomatic 84 24
Mucinous 16 44 .0060
Mixed 9 12
Nonmucinous 75 44
Sclerosing 86 60 .0032
Nonsclerosing 14 40
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2 lymphocyte infiltration, and 22 of 119 patients had
grade 3 lymphocyte infiltration.
Pathologic staging of tumor. Pathologic staging was
performed for each patient undergoing surgical resec-
tion (Table III). Eight-two percent of patients were
either surgical stage I or II.
Incidence of clinical factors. There was no differ-
ence in the average age between men and women.
Thirty-six of the men (82%) were smokers, whereas 44
of the women (59%) were smokers (P = .016). There
was no significant relation between the presence of
symptoms and smoking status.
Correlations among clinical, radiographic, and
pathologic findings. Symptomatic patients (76%)
more often had infiltrative radiographic features, and
asymptomatic patients more often had mass lesions
(84%; P < .0001). There was no correlation between
smoking status and radiographic findings (Table IV).
Infiltrative radiologic findings correlated with muci-
nous histologic findings (P = .0060), and mass lesions
correlated with nonmucinous histologic findings and
the presence of sclerosis (P = .0032). The pathologic
finding of 100% BAC correlated with nonsmokers and
infiltrative lesions. No other significant correlations
Fig 1. Overall survival for patients undergoing surgical resection (n = 107 patients) or open lung biopsy (OLB; n =
7 patients).
Fig 2. Survival for complete (n = 102 resections) versus incomplete resection (n = 5 resections). Complete resec-
tion showed better prognosis than incomplete resection (P < .01)
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existed among the other clinical, radiologic, or patho-
logic factors. 
Factors affecting survival. Median duration of fol-
low-up among the surviving patients after operation
was 6.9 years. Overall survival of patients who under-
went any surgical procedure was 64.8% at 5 years and
53.0% at 10 years. The survival of the patients under-
going surgical resection was 69.1% at 5 years and
56.5% at 10 years (Fig 1). No patient undergoing open
lung biopsy survived more than 21⁄2 years. All the
patients undergoing multiple operations survived more
than 50 months after the initial operation. The exis-
tence of malignant cells in the resected margin corre-
lated with a poor prognosis (P < .01; Fig 2). The sur-
vival according to operative procedure is seen in Fig 3.
Segmentectomy showed a statistically significant better
prognosis than wedge resection (P = .022). The factors
affecting survival by univariate analysis (Table V) were
radiographic findings of mass or infiltrate (Fig 4),
nodal involvement, pathologic findings of sclerosis,
and association with scar. The percent of BAC (Fig 5)
showed a significant difference in survival; 100% pres-
ence of BAC showed a worse prognosis than tumors
with a mixture of BAC and adenocarcinoma (P < .05).
The grade of lymphocyte infiltration (Fig 6) showed
significant differences in survival. Patients with grade 3
lymphocyte infiltration had a better prognosis than
those with grade 0, 1, or 2 (P < .01). Multivariate
analysis showed that nodal involvement and the radio-
logic finding of an infiltrative process had a negative
impact on survival and that the presence of a mass
lesion had a positive impact on survival.
Discussion
BAC represents between 1% and 9% of lung cancers
in most series.4,12,13,15 Confusion has surrounded many
aspects of this tumor. Much of the confusion relates to
the relative infrequency of this tumor, disagreement
among pathologists about the pathologic findings, and
lack of correlation between clinical, radiographic, and
pathologic findings and their impact on survival.
In our series, we found a nearly 2:1 ratio of women
Fig 3. Survival by operative procedure. Segmentectomy (n = 8) showed better prognosis than wedge resection (n
= 13; P < .01).
Table V. Factors adversely affecting survival 
(n = 107)
Factors P value
Clinical features
Symptomatic versus asymptomatic .05
Smoking versus nonsmoking .2
Radiologic findings
Infiltrate versus mass .004
Single versus multiple mass .19
≤3 cm versus >3 cm (single mass) .2
Pathologic findings
Aerogenous spread .8
Mucinous versus nonmucinous .7
Nonsclerosing versus sclerosing .001
No scar versus scar .02
Mitosis 0 and 1 vs 2 .4
Nuclear grade (well/moderate/poor) .6
Rate of BAC 100% versus 50%-90% .02
Lymphocyte grade 0+1 + 2 versus 3 .03
N1+2 versus N0 .001
T1 N0 versus T2 N0 (N0) .2
Margin positive versus negative <.001
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to men. This has been reported by others but not all
authors.4,12,13,15 Because most of our patients had soli-
tary pulmonary nodules, nearly 72% were asympto-
matic. Of these patients having symptoms, 56% had
evidence of infiltrative lesions on radiographs. Sixty-
eight percent of the patients in our series were smokers,
but this did not have an impact on survival.
The most common operation in our series was lobec-
tomy. Some of the neoplasms were more advanced and
required more extensive procedures. Small peripheral
lesions were managed by lobectomy, segmentectomy,
or wedge resection. There was a statistically significant
difference in survival between segmentectomy and
wedge resection. Because of the patterns of spread of
BAC along alveolar walls and by aerogenous routes, it
should be recommended that lobectomy or segmentec-
tomy is preferable for small peripheral neoplasms.
The most common cell type seen was the Clara cell.
Other cell types or mixture of cells were identified.
This suggests a multiclonal origin of this tumor. The
pattern of multiple cells of origin argues that multiple
separate independent primary tumors occur in contigu-
ous foci. This may explain the differences in histologic
evidence seen in some of the recurrent tumors and the
Fig 4. Survival according to the presence of a mass or infiltrate on radiograph. Radiologic mass (n = 93) showed
better prognosis than infiltrate (n = 14; P < .004).
Fig 5. Survival according to percent BAC seen in tumor: 100% BAC showed worse prognosis than 50% to 90%
BAC (P < .05); no significant differences were seen among 50% to 90% BAC.
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frequently observed admixture with typical findings of
adenocarcinoma.14-16 A pure BAC pattern was seen in
only 17 of 119 patients, correlating with an infiltrative
pattern on radiograph. This small subset of patients
correlated with a worse prognosis than those patients
with other percentages of BAC. Most patients in this
series showed histologic signs of sclerosis in the pres-
ence of a scar, and most were nonmucinous as well.
This has been reported by others.6 The presence of
sclerosis and a scar had a positive correlation with sur-
vival, but no impact on survival was found among those
tumors that showed signs of mucin production contrary
to what others have reported.6,17 The differences in pul-
monic involvement in neoplasms with mucinous, non-
mucinous, and sclerosis present histologically are
reported to be due to differences in basement mem-
brane integrity and type IV collagenase activity, which
destroys the basement membrane and facilitates the
spread of tumor through the lymphatic duct.18 The
other interesting histologic finding was the positive
correlation between grade 3 lymphocyte infiltration
and survival. Whether this finding implies a beneficial
host immunologic reaction to the tumor is purely spec-
ulation. Further evaluation of this finding is warranted. 
The overwhelming majority of our patients had stage
I or II neoplasms that represented solitary nodules. This
accounts for the 5- and 10-year survival figures of 69%
and 56%, respectively, in patients undergoing surgical
resection. It was important to achieve complete surgi-
cal resection. The 5-year survival for completely
resected patients was 71% and only 20% for incom-
plete resections (1/5 patients; P < .01). Positive hilar or
mediastinal lymph nodes occurred in only 10% of our
patients but was a statistically significant factor
adversely affecting survival.
Overall, we were able to develop a favorable profile
for patients with BAC. Patients that had no symptoms
and a mass lesion on chest radiograph have a better prog-
nosis. Conversely, those patients with an infiltrative pic-
ture and symptoms had a worse prognosis. Histologi-
cally, the presence of sclerosis and a scar, abundant
infiltration with lymphocytes, and no evidence of lymph
node metastases are associated with a more favorable
prognosis. Patients undergoing complete surgical resec-
tion with these findings have a good prognosis.
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Discussion
Dr Mark S. Allen (Rochester, Minn). Since the initial
description of BAC of the lung in 1876, there has been a con-
siderable amount of controversy about this disease. It does
not seem to behave like a typical bronchogenic carcinoma.
The biology differs from a typical lung cancer because it
seems to be slow growing and may have a multicentric origin
and does not commonly metastasize to the lymphatics.
However, there exists a subset of patients in whom this dis-
ease, unfortunately, behaves quite similarly to a typical bron-
chogenic carcinoma, with a rapid demise despite our best
management. I hope that, as the genetic defects are found that
transform cells into their malignant behavior, we will begin to
understand the differences in these various cancers. 
Until this technologic breakthrough occurs, we will have to
rely on retrospective reviews such as this to learn about this dis-
ease. This article has many similarities to a paper presented at
the meeting of the Southern Thoracic Surgical Association in
1990 by Dr Richard Daly from our own institution. 
The demographics of the patients with BAC are very simi-
lar in the 2 reports; most had a single nodule and were asymp-
tomatic. The operation most commonly performed is a lobec-
tomy, and the mortality rate is quite low. A high percentage of
the patients have stage I disease, and their survival is quite
good compared with the average patient with bronchogenic
carcinoma. 
I have 3 questions. In our series we had quite a few patients
who had recurrence after 5 years. What is your recommenda-
tion for follow-up of this group of patients? Do you obtain a
periodic computed axial tomographic scan or do you obtain
periodic chest x-ray films only? Do you use sputum cytologic
findings in any way to observe these patients? 
My second question concerns patients who have a mass on
one side that is diagnosed as BAC but have infiltrative lesions
on the other side. Do you recommend resecting the larger
lesion first and closely monitoring the contralateral lesion, or
do you try and diagnose the smaller contralateral lesions first? 
Finally, do you think that this is a multicentric disease or do
you think that, in patients who have multiple sites, they all
originated from one focus? 
Dr Okubo. With respect to the third question, I think the
tumor is multicentric because of the variety of cell types,
including Clara cell, type II pneumocyte. This neoplasm shows
a variety of mixed cell types, so I think it is multicentric. 
With respect to the second question, we individualize the
management of bilateral lesions. If the presence of contralat-
eral disease would contraindicate surgical procedures, we
would perform a biopsy of it first. For other reasons we might
monitor them or resect at a later date. 
Usually postoperative follow-up is done with chest x-ray
films and computed axial tomography scans. So, this should
be done for follow-up. We have not found sputum cytologic
evidence to be useful.
Dr Nasser K. Altorki (New York, NY). I am always trou-
bled by the patient who has a diffuse lobar infiltrate and a
diagnosis of BAC. Can you tell me, now knowing what you
know about this series, what your strategy has been or will be
in the treatment of those patients? Is this a surgical disease? 
Dr Okubo. As long as this neoplasm spreads unilaterally,
this is a surgical disease. The diffuse infiltrative lesions tend
to have a worse prognosis, but they tend to respond poorly to
radiation or chemotherapy. There are some patients who have
bronchiolar and diffuse disease who should undergo a resec-
tion to control symptoms.
Dr Lawrence R. Kaiser (Philadelphia, Pa). Just to follow
up on that, how many of the patients in this series who had
lobar infiltrates underwent resection, and were any of those
patients long-term survivors? The issue of the multicentricity
of these lesions is an interesting one. In talking with Rob
Garver, who is one of the pulmonologists at the University of
Alabama, I believe they have performed transplantations in 7
patients with BAC. Two of those patients have experienced
the development of BAC in the transplanted lungs, and they
are currently looking to see whether that is of donor or recip-
ient origin. 
Are there any long-term survivors with resected lobar
infiltrates? 
Dr Okubo. Fourteen of 25 infiltrate regions on radiogra-
phy underwent resections, with a 5-year survival of 30% to
40%; but these were not the patients with lobar or an entire
lung involved. The diffuse, extensive infiltrative lesions are
associated with a much worse prognosis.
